Advanced glycation end products (AGEs) are a group of complex compounds that are formed when proteins or lipids combine with sugars in a non-enzymatic glycation reaction. They can accumulate with age on collagen, skin, tendons and arterial walls. Testing AGEs levels help clinicians determine diabetes complications and degree of glycemic control in patients. The accumulation of AGEs in tissues leads to complications like kidney diseases, heart diseases, neurological complications and peripheral vascular diseases. With rising diabetes cases globally, demand for AGEs testing is expected to increase as well for better diabetes management.

The advanced glycation end products market is estimated to be valued at US$ 3,469.95 million in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the advanced glycation end products market are Novozymes, Agilent Technologies, Merck KGaA, Thermo Fisher Scientific Inc., Cell Biolabs Inc., and Cisbio.

The global burden of diabetes and subsequent growth in demand for disease management through AGEs testing is a key factor driving market growth. According to the International Diabetes Federation, around 537 million adults aged 20-79 years were living with diabetes in 2021.

Technological advancements are facilitating miniaturization and automation of AGEs testing systems. For instance, ELISA-based kits allow quick and easy quantification of specific AGEs in biological samples with high sensitivity and accuracy. Various multiplexed AGEs quantification platforms integrating microfluidics and chemiluminescent detection technologies are also being developed.

Market Trends

- Personalized Medicine: Testing AGEs levels helps determine individual variation in glycemic control and progression of diabetes complications. This is spurring research on AGEs as biomarkers for personalized treatment strategies.

- Alternative Testing Methods: Non-invasive methods to detect AGEs deposition in tissues through fluorescence, near infrared or Raman spectroscopy are gaining focus to enhance convenience and adherence to long-term monitoring.

Market Opportunities

- Expanding Applications: Growing application of AGEs testing in evaluating drug efficacy for diabetes, cardiovascular diseases, and in cancer research present untapped opportunities.

- Emerging Economies: Asia Pacific offers high growth potential attributed to mounting diabetes incidence, increasing healthcare expenditure, and improving access to diagnosis in developing countries.

Advanced Glycation End Products Market Growth During COVID-19
The COVID-19 pandemic has impacted the growth of the Advanced Glycation End Products market in several ways. Globally, the restrictions imposed to curb the spread of the virus disrupted supply chains and manufacturing activities. This negatively affected market demand and revenue growth initially. With the lockdowns, spending on healthcare lessened as people avoided routine checkups and non-critical treatments. However, as the pandemic exposed people to several health risks, awareness about chronic diseases increased. This boosted the focus on finding innovative solutions to emerging health issues like diabetes, cardiovascular diseases, and kidney ailments where AGEs play a role.
Post pandemic, the market is anticipated to see steady recovery backed by rising health consciousness. Manufacturers are expected to ramp up production gradually to cater to the accumulating demand. Simultaneously, investments in R&D are likely to continue and aid product innovation. Telehealth and remote patient monitoring will support market growth through better chronic disease management. Vaccination drives and Covid appropriate behavior can help sustain the regained momentum. Overall, though short term impact was negative, long term prospects of the Advanced Glycation End Products market remain optimistic given the increased health risks and focus on finding therapeutic solutions.

In terms of value, North America holds the major share of the Advanced Glycation End Products market currently due to the rising prevalence of chronic diseases, well-established healthcare system, and advanced research infrastructure. Asia Pacific is positioned as the fastest growing regional market backed by growing medical expenditures, rising living standards, increasing awareness regarding AGE-related conditions, and improvements in healthcare facilities.countries like China and India provide huge untapped opportunities for market players. Meanwhile, Europe and Latin America are also lucrative regions to target.

Focusing on value concentration, the US accounts for the largest share within the North American Advanced Glycation End Products market. This is attributed to factors such as the large patient population, presence of leading manufacturers, and higher acceptance of innovative therapeutics. Within the Asia Pacific region, China holds maximum value currently but India is expanding at a quicker pace due to the huge population base suffering from diabetes and kidney ailments. Japan also captures a notable value portion.